BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34905788)

  • 1. Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.
    Vaassen P; Dürr NR; Rosenbaum T
    Neuropediatrics; 2022 Feb; 53(1):52-60. PubMed ID: 34905788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
    N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Anderson MK; Johnson M; Thornburg L; Halford Z
    Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
    Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A
    Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
    Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
    N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
    Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
    ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
    Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
    J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects.
    Baldo F; Grasso AG; Cortellazzo Wiel L; Maestro A; Trojniak MP; Murru FM; Basso L; Magnolato A; Bruno I; Barbi E
    Paediatr Drugs; 2020 Aug; 22(4):417-423. PubMed ID: 32533336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
    Gross AM; Dombi E; Widemann BC
    Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
    Acar S; Armstrong AE; Hirbe AC
    Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
    Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
    Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
    Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
    J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
    Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
    Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
    Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
    Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
    Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
    Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
    Suenobu S; Terashima K; Akiyama M; Oguri T; Watanabe A; Sugeno M; Higashimori M; So K; Nishida Y
    Neurooncol Adv; 2023; 5(1):vdad054. PubMed ID: 37287695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety profile of selumetinib in symptomatic inoperable plexiform neurofibromas.
    Sharawat IK; Panda PK; Sihag RK; Panda P; Dawman L
    J Neurosurg Sci; 2022 Dec; 66(6):501-510. PubMed ID: 35301838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
    Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N
    J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trametinib Induces Neurofibroma Shrinkage and Enables Surgery.
    Vaassen P; Dürr N; Röhrig A; Willing R; Rosenbaum T
    Neuropediatrics; 2019 Oct; 50(5):300-303. PubMed ID: 31141829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.